What’s in Biodelivery Sciences International Incorporated (NASDAQ:BDSI) After Rise in Shorted Shares?

January 13, 2018 - By Marguerite Chambers

 What’s in Biodelivery Sciences International Incorporated (NASDAQ:BDSI) After Rise in Shorted Shares?

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.67, from 1 in 2017Q2. It is positive, as 8 investors sold BioDelivery Sciences International, Inc. shares while 7 reduced holdings. 6 funds opened positions while 19 raised stakes. 20.34 million shares or 6.83% more from 19.04 million shares in 2017Q2 were reported.
Moreover, Barclays Public Limited Com has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 57 shares. Eam Investors Llc stated it has 780,635 shares or 0.31% of all its holdings. Hikari Pwr Limited holds 0.23% or 601,285 shares in its portfolio. Salem Invest Counselors Inc invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Renaissance Tech Ltd reported 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Sterling Investment Management Incorporated reported 50,000 shares. Us Savings Bank De holds 200 shares or 0% of its portfolio. Next Finance Gp Inc has 0.05% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 58,850 shares. Art Advsrs Limited Liability Corp stated it has 71,455 shares or 0.01% of all its holdings. Bancorporation Of Montreal Can accumulated 968,936 shares. Citadel Advsrs Ltd Liability Company stated it has 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). J Goldman Co L P, a New York-based fund reported 135,000 shares. Moreover, Janney Montgomery Scott Ltd Limited Liability Company has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). 51,562 are held by State Street Corp. Bank & Trust Of America Corporation De holds 2,110 shares or 0% of its portfolio.

Since September 14, 2017, it had 0 buys, and 1 insider sale for $572,601 activity.

The stock of Biodelivery Sciences International Incorporated (NASDAQ:BDSI) registered an increase of 32.48% in short interest. BDSI’s total short interest was 1.43M shares in January as published by FINRA. Its up 32.48% from 1.08 million shares, reported previously. With 561,800 shares average volume, it will take short sellers 3 days to cover their BDSI’s short positions. The short interest to Biodelivery Sciences International Incorporated’s float is 3.29%.

The stock increased 0.89% or $0.025 during the last trading session, reaching $2.825. About 109,360 shares traded. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 24.37% since January 13, 2017 and is uptrending. It has outperformed by 7.67% the S&P500.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $157.87 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 27.97 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 6 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery Sciences International had 30 analyst reports since August 16, 2015 according to SRatingsIntel. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Monday, November 27 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Friday, June 9 report. Roth Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, March 11. Roth Capital has “Buy” rating and $9 target. Piper Jaffray initiated it with “Overweight” rating and $6 target in Monday, February 8 report. The company was maintained on Monday, August 14 by Cantor Fitzgerald. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, June 23. H.C. Wainwright has “Buy” rating and $400 target. As per Friday, September 8, the company rating was initiated by H.C. Wainwright. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) earned “Buy” rating by Roth Capital on Thursday, October 12. The rating was upgraded by Janney Capital on Friday, September 23 to “Buy”. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Thursday, August 10 by H.C. Wainwright.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Seekingalpha.com which released: “BioDelivery Sciences: Belbuca Transition Appears To Have Worked” on May 07, 2017, also Globenewswire.com with their article: “BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical” published on December 14, 2017, Seekingalpha.com published: “BioDelivery Sciences: Change Is Good?” on September 29, 2017. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Prnewswire.com and their article: “BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides …” published on May 15, 2017 as well as Prnewswire.com‘s news article titled: “BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference” with publication date: November 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.